

Display Settings:  AbstractSend to: [Mol Psychiatry](#). 2014 Mar;19(3):317-24. doi: 10.1038/mp.2013.7. Epub 2013 Mar 12.

## Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.

[Smesny S](#)<sup>1</sup>, [Milleit B](#)<sup>1</sup>, [Hipler UC](#)<sup>2</sup>, [Milleit C](#)<sup>3</sup>, [Schäfer MR](#)<sup>4</sup>, [Klier CM](#)<sup>5</sup>, [Holub M](#)<sup>6</sup>, [Holzer I](#)<sup>6</sup>, [Berger GE](#)<sup>7</sup>, [Otto M](#)<sup>1</sup>, [Nenadic I](#)<sup>1</sup>, [Berk M](#)<sup>8</sup>, [McGorry PD](#)<sup>9</sup>, [Sauer H](#)<sup>1</sup>, [Amminger GP](#)<sup>4</sup>.[+ Author information](#)

### Abstract

The identification of an ultra-high risk (UHR) profile for psychosis and a greater understanding of its prodrome have led to increasing interest in early intervention to delay or prevent the onset of psychotic illness. In a randomized placebo-controlled trial, we have identified long-chain  $\omega$ -3 ( $\omega$ -3) polyunsaturated fatty acid (PUFA) supplementation as potentially useful, as it reduced the rate of transition to psychosis by 22.6% 1 year after baseline in a cohort of 81 young people at UHR of transition to psychosis. However, the mechanisms whereby the  $\omega$ -3 PUFAs might be neuroprotective are incompletely understood. Here, we report on the effects of  $\omega$ -3 PUFA supplementation on intracellular phospholipase A2 (inPLA(2)) activity, the main enzymes regulating phospholipid metabolism, as well as on peripheral membrane lipid profiles in the individuals who participated in this randomized placebo-controlled trial. Patients were studied cross-sectionally (n=80) and longitudinally (n=65) before and after a 12-week intervention with 1.2 g per day  $\omega$ -3 PUFAs or placebo, followed by a 40-week observation period to establish the rates of transition to psychosis. We investigated inPLA(2) and erythrocyte membrane FAs in the treatment groups ( $\omega$ -3 PUFAs vs placebo) and the outcome groups (psychotic vs non-psychotic). The levels of membrane  $\omega$ -3 and  $\omega$ -6 PUFAs and inPLA(2) were significantly related. Some of the significant associations (that is, long-chain  $\omega$ -6 PUFAs, arachidonic acid) with inPLA(2) activity were in opposite directions in individuals who did (a positive correlation) and who did not (a negative correlation) transition to psychosis. Supplementation with  $\omega$ -3 PUFA resulted in a significant decrease in inPLA(2) activity. We conclude that  $\omega$ -3 PUFA supplementation may act by normalizing inPLA(2) activity and  $\delta$ -6-desaturase-mediated metabolism of  $\omega$ -3 and  $\omega$ -6 PUFAs, suggesting their role in neuroprogression of psychosis.

PMID: 23478748 [PubMed - indexed for MEDLINE]

[Publication Types, MeSH Terms, Substances](#)[LinkOut - more resources](#)[PubMed Commons](#)[PubMed Commons home](#)

0 comments

[How to join PubMed Commons](#)

### Full text links

[Save items](#)[Add to Favorites](#)[Related citations in PubMed](#)[Long-chain omega-3 fatty acids for i \[Arch Gen Psychiatry. 2010\]](#)[Frontal delta power associated with nega \[Schizophr Res. 2012\]](#)[Omega-3 fatty acid supplen \[Can J Psychiatry. 2013\]](#)[Review Significance of long-chain polyu \[Eur J Pediatr. 2010\]](#)[Review A 'desaturase Nutrigenet Nutrigenomics. 2009\]](#)[See reviews...](#)[See all...](#)[Cited by 2 PubMed Central articles](#)[Biomarkers and clinical staging in psych \[World Psychiatry. 2014\]](#)[Review Prediction and pr \[Ther Clin Risk Manag. 2014\]](#)[Related information](#)[Related Citations](#)[MedGen](#)[PubChem Compound \(MeSH Keyword\)](#)[Cited in PMC](#)[Recent Activity](#)[Turn Off](#) [Clear](#) [Omega-3 fatty acid supplementation char PubMed](#) [Polyunsaturated fatty acids in emerging psychosi PubMed](#) [Fusar-Poli P\[au\] \(215\)](#)

 [Neuropsychopharmacology of psychosis: relation](#) PubMed

 [Brain connectivity abnormalities predati](#) PubMed

[See more...](#)

You are here: [NCBI](#) > [Literature](#) > [PubMed](#)

[Write to the Help Desk](#)

**GETTING STARTED**

- [NCBI Education](#)
- [NCBI Help Manual](#)
- [NCBI Handbook](#)
- [Training & Tutorials](#)

**RESOURCES**

- [Chemicals & Bioassays](#)
- [Data & Software](#)
- [DNA & RNA](#)
- [Domains & Structures](#)
- [Genes & Expression](#)
- [Genetics & Medicine](#)
- [Genomes & Maps](#)
- [Homology](#)
- [Literature](#)
- [Proteins](#)
- [Sequence Analysis](#)
- [Taxonomy](#)
- [Training & Tutorials](#)
- [Variation](#)

**POPULAR**

- [PubMed](#)
- [Bookshelf](#)
- [PubMed Central](#)
- [PubMed Health](#)
- [BLAST](#)
- [Nucleotide](#)
- [Genome](#)
- [SNP](#)
- [Gene](#)
- [Protein](#)
- [PubChem](#)

**FEATURED**

- [Genetic Testing Registry](#)
- [PubMed Health](#)
- [GenBank](#)
- [Reference Sequences](#)
- [Gene Expression Omnibus](#)
- [Map Viewer](#)
- [Human Genome](#)
- [Mouse Genome](#)
- [Influenza Virus](#)
- [Primer-BLAST](#)
- [Sequence Read Archive](#)

**NCBI INFORMATION**

- [About NCBI](#)
- [Research at NCBI](#)
- [NCBI News](#)
- [NCBI FTP Site](#)
- [NCBI on Facebook](#)
- [NCBI on Twitter](#)
- [NCBI on YouTube](#)

Copyright | [Disclaimer](#) | [Privacy](#) | [Browsers](#) | [Accessibility](#) | [Contact](#)  
 National Center for Biotechnology Information, U.S. National Library of Medicine  
 8600 Rockville Pike, Bethesda MD, 20894 USA

